Cite
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
MLA
Curti, Brendan D., et al. “Enhancing Clinical and Immunological Effects of Anti-PD-1 with Belapectin, a Galectin-3 Inhibitor.” Journal for Immunotherapy of Cancer, vol. 9, no. 4, Apr. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-002371.
APA
Curti, B. D., Koguchi, Y., Leidner, R. S., Rolig, A. S., Sturgill, E. R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B., Hilgart-Martiszus, I., Fountain, C. B., Morris, G., Iwamoto, N., Shimada, T., Chang, S., Traber, P. G., Zomer, E., Horton, J. R., Shlevin, H., & Redmond, W. L. (2021). Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. Journal for Immunotherapy of Cancer, 9(4). https://doi.org/10.1136/jitc-2021-002371
Chicago
Curti, Brendan D, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, et al. 2021. “Enhancing Clinical and Immunological Effects of Anti-PD-1 with Belapectin, a Galectin-3 Inhibitor.” Journal for Immunotherapy of Cancer 9 (4). doi:10.1136/jitc-2021-002371.